Geneos Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $85.4K | Sell |
137
-698
| -84% | -$475K | ﹤0.01% | 1270 |
|
|
2026
Q1 | $645K | Buy |
835
+15
| +2% | +$11.5K | 0.02% | 616 |
|
|
2025
Q4 | $633K | Sell |
820
-62
| -7% | -$42.1K | 0.02% | 601 |
|
|
2025
Q3 | $496K | Buy |
882
+102
| +13% | +$57.7K | 0.01% | 651 |
|
|
2025
Q2 | $410K | Buy |
780
+23
| +3% | +$12.8K | 0.01% | 773 |
|
|
2025
Q1 | $480K | Buy |
757
+67
| +10% | +$46.1K | 0.02% | 635 |
|
|
2024
Q4 | $492K | Buy |
690
+3
| +0.4% | +$2.52K | 0.02% | 596 |
|
|
2024
Q3 | $722K | Sell |
687
-119
| -15% | -$132K | 0.03% | 474 |
|
|
2024
Q2 | $847K | Sell |
806
-40
| -5% | -$38.8K | 0.04% | 390 |
|
|
2024
Q1 | $814K | Sell |
846
-18
| -2% | -$17.1K | 0.04% | 388 |
|
|
2023
Q4 | $759K | Sell |
864
-42
| -5% | -$34.6K | 0.04% | 379 |
|
|
2023
Q3 | $746K | Sell |
906
-102
| -10% | -$80.2K | 0.04% | 374 |
|
|
2023
Q2 | $724K | Sell |
1,008
-29
| -3% | -$22.4K | 0.04% | 382 |
|
|
2023
Q1 | $852K | Sell |
1,037
-49
| -5% | -$37K | 0.05% | 326 |
|
|
2022
Q4 | $784K | Sell |
1,086
-37
| -3% | -$27.3K | 0.05% | 321 |
|
|
2022
Q3 | $773K | Buy |
1,123
+8
| +0.7% | +$5.04K | 0.05% | 304 |
|
|
2022
Q2 | $663K | Sell |
1,115
-62
| -5% | -$40.3K | 0.03% | 422 |
|
|
2022
Q1 | $822K | Sell |
1,177
-30
| -2% | -$19K | 0.04% | 415 |
|
|
2021
Q4 | $762K | Sell |
1,207
-23
| -2% | -$14.1K | 0.03% | 470 |
|
|
2021
Q3 | $702K | Sell |
1,230
-191
| -13% | -$119K | 0.03% | 486 |
|
|
2021
Q2 | $829K | Sell |
1,421
-138
| -9% | -$69.9K | 0.03% | 421 |
|
|
2021
Q1 | $750K | Sell |
1,559
-52
| -3% | -$25.3K | 0.02% | 518 |
|
|
2020
Q4 | $767K | Buy |
1,611
+1,265
| +366% | +$683K | 0.03% | 427 |
|
|
2020
Q3 | $198K | Buy |
346
+5
| +1% | +$3.03K | 0.01% | 689 |
|
|
2020
Q2 | $208K | Sell |
341
-196
| -36% | -$111K | 0.01% | 658 |
|
|
2020
Q1 | $245K | Buy |
537
+20
| +4% | +$8.25K | 0.02% | 552 |
|
|
2019
Q4 | $193K | Hold |
517
| – | – | 0.01% | 712 |
|
|
2019
Q3 | $141K | Hold |
517
| – | – | 0.01% | 773 |
|
|
2019
Q2 | $161K | Hold |
517
| – | – | 0.01% | 737 |
|
|
2019
Q1 | $212K | Buy |
517
+7
| +1% | +$2.88K | 0.01% | 621 |
|
|
2018
Q4 | $184K | Sell |
510
-40
| -7% | -$14.6K | 0.01% | 631 |
|
|
2018
Q3 | $222K | Hold |
550
| – | – | 0.01% | 604 |
|
|
2018
Q2 | $189K | Sell |
550
-17
| -3% | -$5.32K | 0.01% | 581 |
|
|
2018
Q1 | $195K | Hold |
567
| – | – | 0.02% | 548 |
|
|
2017
Q4 | $213K | Hold |
567
| – | – | 0.02% | 514 |
|
|
2017
Q3 | $253K | Sell |
567
-1
| -0.2% | -$476 | 0.03% | 448 |
|
|
2017
Q2 | $278K | Sell |
568
-10
| -2% | -$4.38K | 0.03% | 417 |
|
|
2017
Q1 | $223K | Sell |
578
-11
| -2% | -$4.08K | 0.02% | 456 |
|
|
2016
Q4 | $216K | Hold |
589
| – | – | 0.03% | 442 |
|
|
2016
Q3 | $236K | Buy |
589
+11
| +2% | +$4.41K | 0.03% | 410 |
|
|
2016
Q2 | $207K | Hold |
578
| – | – | 0.03% | 432 |
|
|
2016
Q1 | $234K | Buy |
+578
| New | +$238K | 0.04% | 400 |
|
Other funds holding REGN
Geneos Wealth Management's REGN Position: Q2 2026 in Review
Geneos Wealth Management reduced its Regeneron Pharmaceuticals (REGN) stake by 84% in Q2 2026, selling an estimated $475K and leaving 137 shares worth $85.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1270.
Geneos Wealth Management first reported a position in REGN in Q1 2016 and has held it in 42 quarters since. The position peaked at $852K in Q1 2023. 1,338 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Geneos Wealth Management held 137 shares of Regeneron Pharmaceuticals worth $85.4K as of Q2 2026.
- Geneos Wealth Management sold 698 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $475K.
- Regeneron Pharmaceuticals made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #1270 holding.
- Geneos Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 42 quarters since.
- Geneos Wealth Management's Regeneron Pharmaceuticals position peaked at $852K in Q1 2023.
- 1,338 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.